CHO Pharma, Inc.

6586

TW0006586001

Pharmaceuticals

End-of-day quote Taipei Exchange Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
55.2 ^TWD	-0.36%		+0.91%	-20.35%

Mar. 20	CHO Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	CHO Pharma, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	CI

CHO Pharma, Inc.(GTSM:6586) added to S&P Global BMI Index

December 18, 2017 at 12:00 am EST

Latest news about CHO Pharma, Inc.

CHO Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 20	CI
CHO Pharma, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-09	CI
CHO Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-24	CI
CHO Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-24	CI
Oneness and Microbio Signs Agreement with Cho Pharma to Jointly Develop Glycosylation-Based Nucleic Acid Delivery Technology	22-12-20	CI
CHO Pharma, Inc. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-04	CI
CHO Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-02-24	CI
Cho Pharma, Inc. Reports Earnings Results for the Half Year Ended June 30, 2021	21-07-29	CI
Cho Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	21-03-24	CI
Cho Pharma, Inc. Reports Earnings Results for the Half Year Ended June 30, 2020	20-08-12	CI
Cho Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019	20-03-25	CI
Cho Pharma, Inc. Reports Earnings Results for the Half Year Ended June 30, 2019	19-08-07	CI
Cho Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2018	19-03-07	CI
CHO Pharma, Inc.(GTSM:6586) added to S&P Global BMI Index	17-12-18	CI
CHO Pharma Inc. Announces Executive Changes	17-10-23	CI

CHO PHARMA INC. is principally engaged in the development of new drugs related to sugar molecules. The companyâs technology and development can be divided into eight categories according to its patent features, including homogeneous antibody drugs, monoclonal antibodies of cancers and immune-related diseases, carbohydrate-related vaccines and drugs, anti-influenza drugs, the development and application of Saccharin tablets, the development and application of sugar probes, the synthesis identification development and application of sugar molecular, as well as the derivative patents of innovation development plans.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Biopharmaceuticals

	1st Jan change	Capi.
CHO PHARMA, INC.	-20.35%	362M
CSL LIMITED	-4.66%	86.13B
SAMSUNG BIOLOGICS CO.,LTD.	+1.32%	39.82B
BIOGEN INC.	-19.27%	30.42B
UCB	+57.86%	25.23B
BIOMARIN PHARMACEUTICAL INC.	-16.09%	15.35B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.14%	11.95B
INCYTE CORPORATION	-17.69%	11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.00%	11.51B
SWEDISH ORPHAN BIOVITRUM AB	+5.24%	8.71B